Bert Amato
Investor / Director @ Jiffy
Toronto, Canada
Bert Amato is a Venture Partner at Golden Venture Partners. With over 25 years of software and technology experience, as well as a proven track record in early-stage investing, Bert is our resident unicorn hunter.Currently an investor, advisor, and director to multiple technology companies, he co-founded Delrina Corporation, best known for itscommunications software product, WinFax. As Chief Technical Officer of Delrina, he was responsible for all product strategy and R&D. At Delrina, Bert also held the positions of Director and Executive Vice President of the corporation. Acquired by Symantec Corporation for US$415M, Bert served as a Vice President of Symantec.In investing, Bert has had a solid track record, placing his personal angel and seed stage money in ten companies which have sold. He is currently an angel investor in Wattpad, Farelogix, Echoworx and Infinity Quick.Prior to his work with Delrina, Bert held a technical development position at the IBM Canada Research Laboratory and was a co-founder and executive officer of Schematix Computer Systems Inc., a software and consulting company. He has an Honours Engineering degree from the University of Toronto.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Bert Amato invests in
Stages Bert Amato invests in
Countries Bert Amato invests in
Round sizes
Round size
- Seed
- $1.5M–$4.8M
Investment Focus
Industry
- Machine Learning 2 (22%)
- Artificial Intelligence 2 (22%)
- SaaS 1 (11%)
- Content 1 (11%)
- Software 1 (11%)
Stage
- Seed 3 (33%)
- Angel 1 (11%)
- Pre-Seed 1 (11%)
- Series A 1 (11%)
- Series B 1 (11%)
Country
- Canada 3 (33%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Basil Systems
|
Basil’s SaaS platform leverages machine-learning across product, market and regulatory data to provide analytics and insights for medical device and pharmaceutical companies. | $11.5M / Venture - Series Unknown / Apr 29, 2025 | |
BenchSci
|
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | $69.6M / Series D / May 25, 2023 | |
Disco
|
Build your live learning empire. One platform to build, market, and sell live courses, workshops, and learning communities. | $4.8M / Seed / Mar 24, 2021 | |
|
Basil Systems
|
Basil’s SaaS platform leverages machine-learning across product, market and regulatory data to provide analytics and insights for medical device and pharmaceutical companies. | $1.5M / Seed / Mar 16, 2021 | |
|
BenchSci
|
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | $22M / Series B / Feb 04, 2020 | |
|
BenchSci
|
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | $7.3M / Series A / May 02, 2018 | |
|
BenchSci
|
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | $1.8M / Seed / Jul 10, 2017 | |
Wattpad
|
Wattpad is a digital entertainment company providing an online social storytelling platform for original stories.The company utilizes the power of community and technology to enable the creation and distribution of content across a variety of formats. Its flagship app, Wattpad, is home to a community of more than 65 million people who spend over20 billion minutes a month engaged in original stories. Tap by Wattpad, the company’s second storytelling product, offers short, chat-based stories in over a dozen languages. Wattpad Studios co-produces stories for film, television, digital, and print, together with industry partners. Wattpad Brand Solutions offers a full suite of advertising products to help brands build deep engagement with Millennial and Gen Z consumers.It was established by Allen Lau and Ivan Yuen in Toronto, Ontario, Canada in 2006. | Angel | |
|
BenchSci
|
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | Pre-Seed |
Co-Investors
About Jiffy
Jiffy is an online platform that connects homeowners with home service providers in real time, based on proximity and availability. These professionals are all pre-vetted. Jiffy was launched by Paul Arlin, Ryan Shupak, and Jaimie Grossman in April 2015 and is based in Toronto, Ontario.
Jiffy Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bert Amato
Investor / Director
|
|||
Jaimie Grossman
Co-founder
|
|||
Paul Arlin
Co-founder
|
|||
Ryan Shupak
Co-founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bert Amato invest in?
Bert Amato invests primarily in Machine Learning, Artificial Intelligence and SaaS startups, most often at Seed and Angel stage. Most of the 9 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bert Amato's check size?
Bert Amato typically joins rounds of $1.5M–$4.8M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bert Amato participates in.
When did Bert Amato last invest?
The most recent investment recorded for Bert Amato closed in Apr 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
